Warning! GuruFocus detected
5 Severe warning signs
with IF0.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
InflaRx NV
NAICS : 541720
SIC : 2834
ISIN : NL0012661870
Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 65.63 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.62 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.8 | |||||
| 3-Year EPS without NRI Growth Rate | 12.5 | |||||
| 3-Year FCF Growth Rate | 7.3 | |||||
| 3-Year Book Growth Rate | -26.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.29 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 526.49 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.34 | |||||
| 9-Day RSI | 30.28 | |||||
| 14-Day RSI | 31.09 | |||||
| 3-1 Month Momentum % | -47.85 | |||||
| 6-1 Month Momentum % | -13.08 | |||||
| 12-1 Month Momentum % | -16.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.06 | |||||
| Quick Ratio | 4.57 | |||||
| Cash Ratio | 3.73 | |||||
| Days Inventory | 1105.32 | |||||
| Days Sales Outstanding | 107.7 | |||||
| Days Payable | 1161.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -1.36 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -1805.46 | |||||
| Operating Margin % | -31377.05 | |||||
| Net Margin % | -27388.53 | |||||
| FCF Margin % | -29278.92 | |||||
| ROE % | -56.95 | |||||
| ROA % | -48.6 | |||||
| ROIC % | -408.64 | |||||
| 3-Year ROIIC % | 5.2 | |||||
| ROC (Joel Greenblatt) % | -1170.49 | |||||
| ROCE % | -56.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 338.14 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 0.94 | |||||
| EV-to-EBIT | -0.22 | |||||
| EV-to-Forward-EBIT | -8.19 | |||||
| EV-to-EBITDA | -0.22 | |||||
| EV-to-Forward-EBITDA | -8.19 | |||||
| EV-to-Revenue | 58.56 | |||||
| EV-to-Forward-Revenue | 17.87 | |||||
| EV-to-FCF | -0.2 | |||||
| Price-to-Net-Current-Asset-Value | 1 | |||||
| Price-to-Net-Cash | 1.51 | |||||
| Earnings Yield (Greenblatt) % | -459.61 | |||||
| FCF Yield % | -76.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InflaRx NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.166 | ||
| EPS (TTM) (€) | -0.79 | ||
| Beta | 0.87 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.48 | ||
| Volatility % | 93.87 | ||
| 14-Day RSI | 31.09 | ||
| 14-Day ATR (€) | 0.08213 | ||
| 20-Day SMA (€) | 1.088775 | ||
| 12-1 Month Momentum % | -16.27 | ||
| 52-Week Range (€) | 0.8845 - 2.614 | ||
| Shares Outstanding (Mil) | 67.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InflaRx NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InflaRx NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
InflaRx NV Frequently Asked Questions
What is InflaRx NV(STU:IF0)'s stock price today?
The current price of STU:IF0 is €0.92. The 52 week high of STU:IF0 is €2.61 and 52 week low is €0.88.
When is next earnings date of InflaRx NV(STU:IF0)?
The next earnings date of InflaRx NV(STU:IF0) is 2025-05-08 Est..
Does InflaRx NV(STU:IF0) pay dividends? If so, how much?
InflaRx NV(STU:IF0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers